Medicenna Therapeutics (TSE:MDNA) Stock Price Down 2.1% – Should You Sell?

Medicenna Therapeutics Corp. (TSE:MDNA) dropped 2.1% during trading on Tuesday . The company traded as low as C$0.45 and last traded at C$0.46. 16,293 shares traded hands during mid-day trading, a decline of 82% from the average daily volume of 91,649 shares. The stock had previously closed at C$0.47.

Medicenna Therapeutics Price Performance

The company has a debt-to-equity ratio of 6.22, a current ratio of 1.25 and a quick ratio of 4.65. The stock’s 50 day simple moving average is C$0.40 and its two-hundred day simple moving average is C$0.53. The stock has a market cap of C$38.77 million, a price-to-earnings ratio of -1.91 and a beta of 3.00.

Medicenna Therapeutics (TSE:MDNA) last announced its quarterly earnings data on Thursday, June 25th. The company reported C($0.05) earnings per share (EPS) for the quarter. Medicenna Therapeutics had a negative net margin of 533,640.00% and a negative return on equity of 360.29%. On average, analysts forecast that Medicenna Therapeutics Corp. will post -0.37 earnings per share for the current fiscal year.

About Medicenna Therapeutics

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.